Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HB-adMSCs in Alzheimer's Disease
NCT04228666Phase 2Withdrawn
- Sponsor
- Hope Biosciences
- Start
- Mar 2020
- Primary completion
- Feb 2022
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of allogeneic HB-adMSCs in Alzheimer's disease (AD), sponsored by Hope Biosciences. Primary endpoints: Adverse Events and Severe Adverse Events and Clinical Laboratory Safety Parameters at Week 52. Planned start Mar 2020; status: withdrawn.
02
Drugs
allogeneic HB-adMSCs
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04228666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04228666.